Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCGB Conditioning for High-Risk Lymphoma
NCT03602131Phase 2Unknown
- Sponsor
- Sichuan University
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tucidinostat in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), sponsored by Sichuan University. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03602131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602131.